Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Schuler, Martin, Fischer, Jürgen R., Grohé, Christian, Gütz, Sylvia, Thomas, Michael, Kimmich, Martin, Schneider, Claus-Peter, Laack, Eckart, Märten, Angela, for the Afatinib Compassionate Use Consortium
Background. Afatinib, an irreversible ErbB family blocker, demonstrated superiority to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Afatinib is also active in patients progressing on EGFR tyro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a46a8204286ec82fd3fd5433cccef10
https://europepmc.org/articles/PMC4200993/
https://europepmc.org/articles/PMC4200993/
Autor:
José I. Echeveste, Miguel Angel Idoate, Luis M. Seijo, Anabel del Barrio, Javier J. Zulueta, Jose Luis Perez-Gracia, Ruben Pio, Salvador Martín-Algarra, Maria D. Lozano, Alfonso Gurpide, Tania Labiano
Objective. Epidermal growth factor receptor (EGFR) and K-ras mutations guide treatment selection in non-small cell lung cancer (NSCLC) patients. Although mutation status is routinely assessed in biopsies, cytological specimens are frequently the only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa127a85a8147e57966ef81bc557058
https://europepmc.org/articles/PMC3228207/
https://europepmc.org/articles/PMC3228207/